Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

BACKGROUND: Amrubicin chemotherapy is a treatment option for patients with non‐small cell lung cancer (NSCLC) after third‐line treatment in Japan. Although topoisomerase‐II (Topo‐II), a target of amrubicin, has been reported to be a prognostic or predictive marker for chemosensitivity and clinical o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Thorac Cancer
Egile Nagusiak: Sakurai, Reiko, Kaira, Kyoichi, Miura, Yosuke, Sunaga, Noriaki, Saito, Ryusei, Oyama, Tetsunari, Hisada, Takeshi, Yamada, Masanobu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons Australia, Ltd 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997014/
https://ncbi.nlm.nih.gov/pubmed/31901017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13289
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak